Ginkgo Bioworks Holdings Inc vs Vanguard S&P 500 ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.08 (market cap $590.53M), while Vanguard S&P 500 ETF trades at $691.83. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | VOO | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $16.14 | $698.29 |
52-Week Low | $5.48 | $571.45 |
Enterprise Value | $627.78M | — |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
VOO, the Vanguard S&P 500 ETF, trades at $688.55, down 0.76% over the past day. Technical indicators show a bullish moving average trend but neutral oscillators, with support near $686 and resistance at $692. The ETF provides diversified exposure to large-cap U.S. stocks, with a dividend of $1.96 scheduled for June 2026. Recent news highlights ongoing discussions about S&P 500 valuations and potential market catalysts from earnings season.
Outlook remains tied to broad market performance, with analysts projecting further S&P 500 gains amid economic resilience. Risks include market volatility and high valuations. The ETF offers a low-cost, passive investment avenue, but investors should monitor macroeconomic trends and earnings results for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →